Johnson & Johnson $JNJ Stake Decreased by Apollon Wealth Management LLC

Apollon Wealth Management LLC lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.8% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 110,132 shares of the company’s stock after selling 940 shares during the quarter. Apollon Wealth Management LLC’s holdings in Johnson & Johnson were worth $16,823,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the business. Fifth Third Wealth Advisors LLC raised its holdings in shares of Johnson & Johnson by 23.8% during the second quarter. Fifth Third Wealth Advisors LLC now owns 32,942 shares of the company’s stock valued at $5,032,000 after buying an additional 6,329 shares during the last quarter. Natural Investments LLC raised its holdings in Johnson & Johnson by 12.6% during the second quarter. Natural Investments LLC now owns 7,342 shares of the company’s stock worth $1,121,000 after purchasing an additional 823 shares in the last quarter. IRON Financial LLC raised its holdings in Johnson & Johnson by 0.6% during the second quarter. IRON Financial LLC now owns 10,646 shares of the company’s stock worth $1,626,000 after purchasing an additional 68 shares in the last quarter. One Degree Advisors Inc raised its holdings in Johnson & Johnson by 28.1% during the second quarter. One Degree Advisors Inc now owns 1,594 shares of the company’s stock worth $243,000 after purchasing an additional 350 shares in the last quarter. Finally, Avion Wealth raised its holdings in Johnson & Johnson by 11.1% during the second quarter. Avion Wealth now owns 1,169 shares of the company’s stock worth $193,000 after purchasing an additional 117 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 0.1%

NYSE JNJ opened at $190.88 on Tuesday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $192.10. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The stock has a market cap of $459.71 billion, a price-to-earnings ratio of 20.42, a PEG ratio of 2.40 and a beta of 0.40. The firm’s 50 day moving average price is $178.88 and its two-hundred day moving average price is $163.97.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm had revenue of $24.02 billion for the quarter. Equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.7%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson’s payout ratio is presently 55.61%.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Piper Sandler reissued an “overweight” rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Wells Fargo & Company set a $212.00 target price on Johnson & Johnson and gave the stock an “overweight” rating in a report on Friday, October 3rd. JPMorgan Chase & Co. boosted their target price on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a report on Tuesday, September 16th. Barclays lifted their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 17th. Finally, Sanford C. Bernstein lifted their price target on shares of Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research report on Monday, October 6th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $192.94.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.